Colin Watts
Affiliations: | 2006-2009 | Brain Repair Centre | University of Cambridge, Cambridge, England, United Kingdom |
Google:
"Colin Watts"Mean distance: 15.67 (cluster 6) | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bulstrode H, Girdler GC, Gracia T, et al. (2022) Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron |
| Kremer AN, Bausenwein J, Lurvink E, et al. (2020) Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase. Frontiers in Immunology. 11: 381 |
| Spiteri I, Caravagna G, Cresswell GD, et al. (2018) Evolutionary dynamics of residual disease in human glioblastoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology |
| Maxan A, Mason S, Saint-Pierre M, et al. (2018) Outcome of cell suspension allografts in a patient with Huntington's disease. Annals of Neurology |
| Palfi S, Gurruchaga JM, Ralph SG, et al. (2016) 367. A Dopamine Gene Therapy for Advanced PD: 4 Years Phase I/II Clinical Update Molecular Therapy. 24: S147 |
| Piccirillo SG, Colman S, Potter NE, et al. (2015) Genetic and functional diversity of propagating cells in glioblastoma. Stem Cell Reports. 4: 7-15 |
| Piccirillo SGM, Colman S, Potter NE, et al. (2015) Abstract 2318: Genetic and functional diversity of propagating cells in glioblastoma Cancer Research. 75: 2318-2318 |
| Piccirillo SGM, Colman S, Potter N, et al. (2015) Op14Genetic And Functional Diversity Of Propagating Cells In Glioblastoma Neuro-Oncology. 17 |
| Watts C, Piccirillo S, Colman S, et al. (2015) Atps-93Chemo-Naïve Glioblastoma Patients Contain Genetically Heterogeneous Sub-Clones Capable Of Tumour Propagation And Spatially Heterogeneous Drug-Resistant Cell Populations Neuro-Oncology. 17 |
| Palfi S, Gurruchaga JM, Ralph GS, et al. (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 383: 1138-46 |